Misonix Reports Strong Revenue Increases for the Three Months and Full-Year Ended June 30, 2012
FARMINGDALE, N.Y., Sept. 18, 2012 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, cranial maxillo – facial surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today reported financial results for the fourth quarter and the fiscal year ending June 30, 2012.
Highlights for the quarter and the fiscal year include:Sales for the fourth quarter of fiscal 2012 increased 41% to $5.3 million compared to $3.8 million in the comparable quarter of fiscal 2011. For the fiscal year, revenues increased 27% to $15.7 million compared to $12.4 million for the full year ending June 30, 2011. Gross margin increased 100 basis points to 58% for the three months ended June 30, 2012 versus June 30, 2011. For the fiscal year, gross margin increased 150 basis points to 59%. BoneScalpel™ revenues increased 82% for the fourth quarter versus the prior year three month period. For the fiscal year, BoneScalpel revenues increased 92% versus the comparable period last year. SonicOne™ revenues increased 89% for the fourth quarter versus the comparable quarter of fiscal 2011. SonicOne revenues increased 17% for the fiscal year versus the comparable period last year. SonaStar™ revenues increased 21% for the fourth quarter versus the comparable quarter of fiscal 2011. SonaStar revenues increased 44% for the fiscal year versus the comparable period last year. Net income for the quarter was $444,813, or $0.06 per diluted share, compared to a net loss of $1.45 million, or $(0.21) per diluted share in the fourth quarter of 2011. For the full year, the Company reported net income of $366,325, or $0.05 per diluted share, compared to a